DREPAN'OS: Prevalence of Osteoporosis in Sickle Cell Disease
Study Details
Study Description
Brief Summary
Sickle cell disease is the most common single-gene disease in the world. Its prevalence is increasing in France, with patients' life expectancy increasing into developed countries. It mainly affects populations originating from sub-Saharan Africa. Among the chronic bone complications associated with sickle cell disease, osteoporosis has previously been highlighted but remains a poorly known complication in this very particular context. A dedicated evaluation of osteoporosis and associated risk factors in sickle cell disease patients living in France may enable better bone management of these patients in the future, as this problem, specific to their disease, is likely to become more frequent as their life expectancy increases.
This is a prospective interventional and monocentric study whose objective is to describe the prevalence of osteoporosis in black patients with sickle cell disease in France
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
sickle cell disease patients 150 black patients with sickle cell disease living in France, 20 to 40 years old will be included in this study |
Other: Questionnaire
For each subject recruited, will be collected for the study a questionnaire looking for a history of low energy fracture, and the origins of the patient (or relatives), as well as medical history, lifestyle (alcohol and tobacco consumption), weight and height. This data will be used for the secondary outcomes.
|
Outcome Measures
Primary Outcome Measures
- Bone mineral density [Day 1]
Bone mineral density is measured by systematic bone densitometry at 3 sites: lumbar spine, femoral neck and total hip. These data will be collected in the patient's medical record
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Black-skinned men and women
-
Aged 20 to 40 years old
-
Sickle cell patients
-
Non-opposition to participate in the study
Exclusion Criteria:
-
Refusal to participate in the study
-
Hemoglobinopathy other than sickle cell disease
-
Severe or End Stage Renal Failure
-
Long-term corticosteroid therapy (>3 months)
-
History of solid cancer or malignant haemopathy
-
History of organ transplantation
-
Pregnant or breastfeeding woman
-
Psychiatric pathology seriously impeding understanding
-
Difficulty understanding oral French
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Hôpital Edouard Herriot | Lyon | France | 69437 |
Sponsors and Collaborators
- Hospices Civils de Lyon
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 69HCL20_0142
- 2020-A00490-39